Patents Assigned to Genentech
  • METHOD TO IMPROVE VIRUS FILTRATION CAPACITY
    Publication number: 20220306726
    Abstract: The present invention relates to the field of protein purification. In particular, the invention concerns methods for increasing the filtration capacity of virus filters, by combined use of endotoxin removal and cation-exchange media in the prefiltration process.
    Type: Application
    Filed: December 7, 2021
    Publication date: September 29, 2022
    Applicant: Genentech, Inc.
    Inventor: Amit Mehta
  • Pyrazolopyrimidine inhibitors of JAK kinases and uses thereof
    Patent number: 11453671
    Abstract: Compounds of formula (I) wherein R1, R2, R3, R4, R5 and R6 are as defined herein, and salts thereof that are useful as JAK kinse inhibitors are described herein. Also provided are pharmaceutical compositions that include such a JAK inhibitor and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of treating or lessening the severity of a disease or condition responsive to the inhibition of a Janus kinase activity in a patient.
    Type: Grant
    Filed: June 16, 2020
    Date of Patent: September 27, 2022
    Assignee: Genentech, Inc.
    Inventors: Mark Edward Zak, Naomi S. Rajapaksa, Yun-Xing Cheng, Jessica Grandner, Daniel G. M. Shore, Marian C. Bryan
  • METHODS AND FORMULATIONS FOR REDUCING RECONSTITUTION TIME OF LYOPHILIZED POLYPEPTIDES
    Publication number: 20220298263
    Abstract: The present invention relates to methods and formulations useful for reducing the reconstitution time of lyophilized polypeptides.
    Type: Application
    Filed: June 3, 2022
    Publication date: September 22, 2022
    Applicant: Genentech, Inc.
    Inventors: Fredric John LIM, Jacob Edward LUOMA, Isidro Angelo Eleazar ZARRAGA, Christopher Michael HEYNES
  • FLT3 LIGAND FUSION PROTEINS AND METHODS OF USE
    Publication number: 20220289803
    Abstract: The invention provides an effectoriess immunoglobulin Fc protein, fusions of the effectorless Fc protein to a Flt3 ligand, and methods of using the same.
    Type: Application
    Filed: May 23, 2022
    Publication date: September 15, 2022
    Applicant: Genentech, Inc.
    Inventors: Yichin LIU, Christine Carine MOUSSION, Travis William BAINBRIDGE, Iraj HOSSEINI, Gregory Alan LAZAR, Sivan COHEN, Christopher Charles KEMBALL, Jill M. SCHARTNER
  • Use of human epididymis protein 4 (HE4) for assessing responsiveness of MUC 16-positive cancer treatment
    Patent number: 11440969
    Abstract: The present invention relates to methods and kits or articles of manufacture related thereto that may find use, inter alia, in assessing responsiveness of cancers to MUC16 antagonists by monitoring HE4 expression. In some embodiments, the methods include measuring the level of expression of HE4 in a sample from a subject; comparing the level of expression of HE4 in the sample with the level of expression of HE4 in a sample previously obtained from the subject; and, optionally, administering to the subject a therapeutically effective amount of a MUC16 antagonist.
    Type: Grant
    Filed: January 4, 2019
    Date of Patent: September 13, 2022
    Assignee: Genentech, Inc.
    Inventors: Mark Lackner, Daniel Maslyar, Yulei Wang, Walter Darbonne, Eric Humke
  • THERAPEUTIC COMPOUNDS AND METHODS OF USE
    Publication number: 20220281819
    Abstract: The invention relates to compounds and methods of using said compounds, as well as pharmaceutical compositions containing such compounds, for treating diseases and conditions mediated by TEAD, such as cancer.
    Type: Application
    Filed: May 12, 2022
    Publication date: September 8, 2022
    Applicant: Genentech, Inc.
    Inventors: Jason Robert Zbieg, James John Crawford, Christian N. Cunningham
  • TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF
    Publication number: 20220281893
    Abstract: Provided herein are tetracyclic oxazepinyl compounds useful in the treatment on cancers.
    Type: Application
    Filed: February 7, 2022
    Publication date: September 8, 2022
    Applicant: Genentech, Inc.
    Inventors: Lewis J. GAZZARD, Samantha Alyson GREEN, Matthew Leo LANDRY, Sushant MALHOTRA, Michael SIU, Steven DO, Yun-Xing CHENG, Limin CHENG, Jianfeng XIN, Mingtao HE
  • Uses of IL-13 antagonists for treating atopic dermatitis
    Patent number: 11434286
    Abstract: Uses of IL-13 antagonists for treating atopic dermatitis are provided. Also provided are methods of treating atopic dermatitis and methods of reducing the severity of atopic dermatitis by administering IL-13 antagonists.
    Type: Grant
    Filed: March 18, 2019
    Date of Patent: September 6, 2022
    Assignee: Genentech Inc.
    Inventors: ChinYu Lin, Theodore A. Omachi, Ryan P. Owen, Karl Yen, Yanan Zheng, Kendra Debusk
  • Pyrazolo[1,5a]pyrimidine derivatives as IRAK4 modulators
    Patent number: 11434250
    Abstract: Compounds of Formula I and methods of use as Interleukin-1 Receptor Associated Kinase 4 (IRAK4) inhibitors are described herein.
    Type: Grant
    Filed: April 30, 2020
    Date of Patent: September 6, 2022
    Assignee: Genentech, Inc.
    Inventors: Marian C. Bryan, Joy Drobnick, James Richard Kiefer, Jr., Aleksandr Kolesnikov, Naomi S. Rajapaksa
  • Methods of identifying bacteria comprising binding polypeptides
    Patent number: 11434482
    Abstract: The invention provides methods of identifying bacteria comprising binding polypeptides. The invention also provides methods of identifying bacteria with improved expression of binding polypeptides. The invention also provides methods of identifying binding polypeptides with improved expression. The invention also provides engineered bacteria suitable for use in the methods of the invention. The invention also provides compositions that can be obtained using the methods, for example, anti-interleukin-13 (IL-13) antibodies with improved expression and/or stability. The invention also provides libraries comprising binding polypeptide (e.g., antibody) variants.
    Type: Grant
    Filed: October 12, 2017
    Date of Patent: September 6, 2022
    Assignee: Genentech, Inc.
    Inventors: Twyla Noelle Lombana, Rebekah McKenna, Christoph Spiess, Karthik Veeravalli, Michael Dillon
  • Anti-IL13 antibodies and uses thereof
    Patent number: 11434287
    Abstract: The present invention relates to anti-IL13 antibodies that bind specifically and with high affinity to both glycosylated and non-glycosylated human IL13, does not bind mouse IL13, and neutralize human IL13 activity at an approximate molar ratio of 1:2 (MAb:IL13). The invention also relates to the use of these antibodies in the treatment of IL13-mediated diseases, such as allergic disease, including asthma, allergic asthma, non-allergic (intrinsic) asthma, allergic rhinitis, atopic dermatitis, allergic conjunctivitis, eczema, urticaria, food allergies, chronic obstructive pulmonary disease, ulcerative colitis, RSV infection, uveitis, scleroderma, and osteoporosis.
    Type: Grant
    Filed: November 13, 2019
    Date of Patent: September 6, 2022
    Assignee: Genentech, Inc.
    Inventors: Sek Chung Fung, Matthew Moyle, Mason Lu, Changning Yan, Sanjaya Singh, Dan Huang
  • Anti-Tau antibodies and methods of use
    Patent number: 11427629
    Abstract: The invention provides anti-Tau antibodies and methods of using the same.
    Type: Grant
    Filed: June 5, 2020
    Date of Patent: August 30, 2022
    Assignees: AC Immune SA, Genentech, Inc.
    Inventors: Oskar Adolfsson, Isidro Hotzel, Danielle DiCara
  • DOSAGE FORM COMPOSITIONS COMPRISING AN INHIBITOR OF BRUTON'S TYROSINE KINASE
    Publication number: 20220267340
    Abstract: The invention relates generally crystalline mesylate salts, crystalline chloride salts and crystalline sulfate salts of the compound (S)-2-(3?-(hydroxymethyl)-1-methyl-5-((5-(2-methyl-4-(oxetan-3-yl)piperazin-1-yl)pyridin-2-yl)amino)-6-oxo-1,6-dihydro-[3,4?-bipyridin]-2?-yl)-7,7-dimethyl-2,3,4,6,7,8-hexahydro-1H-cyclopenta[4,5]pyrrolo[1,2-a]pyrazin-1-one that is an inhibitor of Bruton's tyrosine kinase. In some aspects, the crystalline salts are single polymorphs.
    Type: Application
    Filed: May 9, 2022
    Publication date: August 25, 2022
    Applicant: Genentech, Inc.
    Inventors: Chen MAO, Dawen KOU, Po-Chang CHIANG
  • COMBINATION THERAPY OF A TYPE II ANTI-CD20 ANTIBODY WITH A SELECTIVE BCL-2 INHIBITOR
    Publication number: 20220265642
    Abstract: The present invention is directed to a combination therapy involving a type II anti-CD20 antibody and a selective Bcl-2 inhibitor for the treatment of a patient suffering from cancer, particularly, a CD20-expressing cancer.
    Type: Application
    Filed: March 30, 2022
    Publication date: August 25, 2022
    Applicants: GENENTECH, INC., HOFFMANN-LA ROCHE INC., ABBVIE INC.
    Inventors: Deepak Sampath, Christian Klein, Wayne John Fairbrother, Sari L. Heitner Enschede, Rod A. Humerickhouse, Andrew W. Roberts, John F. Seymour
  • COMPOSITIONS AND METHODS OF TREATING LUPUS NEPHRITIS
    Publication number: 20220259321
    Abstract: The present disclosure provides methods for treating lupus nephritis in an individual that has lupus. In some embodiments, the methods comprise administering to the individual an effective amount of a type II anti-CD20 antibody. In other aspects, the present disclosure provides methods for treating membranous nephropathy.
    Type: Application
    Filed: March 10, 2022
    Publication date: August 18, 2022
    Applicant: Genentech, Inc.
    Inventor: Matthew Dominic CASCINO
  • METHODS OF TREATING CANCER
    Publication number: 20220257592
    Abstract: Provided herein are methods of treating cancer in a patient in need thereof includes administering to the patient a therapeutically effective amount of entrectinib wherein the patient has impaired hepatic function and methods of managing adverse reactions of administration of entrectinib in a patient.
    Type: Application
    Filed: February 1, 2022
    Publication date: August 18, 2022
    Applicants: HOFFMANN-LA ROCHE INC., IGNYTA, INC., GENENTECH, INC.
    Inventors: Georgina Meneses-Lorente, Edna Chow Maneval, Pratik S. Multani, Susan Diane Eng, Sergio Rene Ley Acosta
  • Combination therapy of a type II anti-CD20 antibody with a selective BCL-2 inhibitor
    Patent number: 11413282
    Abstract: The present invention is directed to a combination therapy involving a type II anti-CD20 antibody and a selective BCL-2 inhibitor for the treatment of a patient suffering from cancer, particularly, a CD20-expressing cancer.
    Type: Grant
    Filed: November 30, 2016
    Date of Patent: August 16, 2022
    Assignees: GENENTECH, INC., HOFFMANN-LA ROCHE INC., ABBVIE INC.
    Inventors: Deepak Sampath, Christian Klein, Wayne John Fairbrother
  • Process for making compounds for use in the treatment of cancer
    Patent number: 11414396
    Abstract: Disclosed herein is a process of making a compound of formula I The compound of formula I is an inhibitor of MEK and thus can be used to treat cancer.
    Type: Grant
    Filed: August 26, 2020
    Date of Patent: August 16, 2022
    Assignees: Exelixis, Inc., Genentech, Inc.
    Inventors: Sriram Naganathan, Nathan Guz, Matthew Pfeiffer, C. Gregory Sowell, Tracy Bostick, Jason Yang, Amit Srivastava, Neel Kumar Anand
  • Composition comprising antibody that binds to domain II of HER2 and acidic variants thereof
    Patent number: 11414498
    Abstract: A composition comprising a main species HER2 antibody that binds to domain II of HER2 and acidic variants thereof is described. Pharmaceutical formulations comprising the composition, and therapeutic uses for the composition are also disclosed.
    Type: Grant
    Filed: July 3, 2019
    Date of Patent: August 16, 2022
    Assignee: Genentech, Inc.
    Inventors: Reed J Harris, Paul A. Motchnick
  • Anti-B7-H4 Antibodies and Immunoconjugates
    Publication number: 20220251213
    Abstract: The invention provides anti-B7-H4 antibodies and immunoconjugates and methods of using the same.
    Type: Application
    Filed: February 22, 2022
    Publication date: August 11, 2022
    Applicant: Genentech, Inc.
    Inventors: Steven R. Leong, Andrew Polson, Paul Polakis, Yan Wu, Wei-Ching Liang, Ron Firestein